Eric T. Shinohara and Adriana Gonzalez contributed equally to this publication.
Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma
Version of Record online: 1 MAR 2005
Copyright © 2005 American Cancer Society
Volume 103, Issue 8, pages 1685–1692, 15 April 2005
How to Cite
Shinohara, E. T., Gonzalez, A., Massion, P. P., Chen, H., Li, M., Freyer, A. S., Olson, S. J., Andersen, J. J., Shyr, Y., Carbone, D. P., Johnson, D. H., Hallahan, D. E. and Lu, B. (2005), Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma. Cancer, 103: 1685–1692. doi: 10.1002/cncr.20951
- Issue online: 4 APR 2005
- Version of Record online: 1 MAR 2005
- Manuscript Revised: 15 DEC 2004
- Manuscript Accepted: 15 DEC 2004
- Manuscript Received: 14 OCT 2004
- Vanderbilt Discovery Grant
- Vanderbilt Physician Scientist Grant. Grant Numbers: VICC CCSG5, R01-CA88076, R01-CA89674, NCI P50-CA90949
- lung carcinoma;
- tissue array;
Survivin, which is a member of the inhibitor of apoptosis protein gene family, regulates both programmed cell death and mitosis. It has been shown that survivin expression and its subcellular localization both have prognostic value for patients with malignant disease. In this study, the authors investigated whether nuclear or cytoplasmic staining of survivin was a prognostic marker for patients with lung carcinoma.
Paraffin-embedded tissue blocks from 144 patients with Stage I and II resected nonsmall cell lung carcinoma (NSCLC) were obtained for immunohistochemical staining. Three specimens from each patient were prepared and stained with a survivin-specific antibody. Nuclear and cytoplasmic staining was graded from 1 to 3 based on intensity.
Patients who had nuclear staining for survivin had a significantly increased risk of disease recurrence (hazard ratio, 2.95; P = 0.0046) and death (hazard ratio, 2.74; P = 0.0086).
The nuclear presence of survivin may be an independent biomarker for disease recurrence and overall survival in patients with resected Stage I and II NSCLC. Cancer 2005. © 2005 American Cancer Society.